Biohaven (BHVN) EPS (Basic) (2021 - 2026)

Biohaven (BHVN) posted EPS (Basic) of -$0.88 for Q1 2026, up 34.62% sequentially from -$1.35 in Q4 2025, and up 59.33% YoY from -$0.55 in Q1 2025.

Analysis

Biohaven (BHVN) EPS (Basic) (2021 - 2026) Analysis & Trends

Biohaven has reported EPS (Basic) for 6 years, with the latest figure at -$0.88 in Q1 2026.

Quarterly EPS (Basic) rose 59.33% year-over-year to -$0.88 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.39 (up 49.66% YoY) and the FY2025 annual result came in at -$6.86, up 26.01% from the prior year.
EPS (Basic) grew to -$0.88 in Q1 2026 per BHVN's latest filing, from -$1.35 in the prior quarter.
Over five years, EPS (Basic) peaked at -$0.88 in Q1 2026 and troughed at -$5.16 in Q2 2022.
A 5-year average of -$2.2 and a median of -$1.94 in 2025 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2022 and 2023: EPS (Basic) sank 241.11% in 2022, then soared 74.36% in 2023.
Over 5 years, EPS (Basic) stood at -$4.49 in 2022, then surged by 54.77% to -$2.03 in 2023, then declined by 0.73% to -$2.05 in 2024, then surged by 33.96% to -$1.35 in 2025, then surged by 34.62% to -$0.88 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.88, -$1.35, and -$1.64 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	139.27 Bn	131.42 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	85.55 Bn	77.56 Bn	3.93 Bn	12.62
3	Argenx Se	63.45 Bn	58.27 Bn	1.37 Bn	7.70
4	Moderna	57.73 Bn	52.59 Bn	52.00 Mn	-1.96
5	Revolution Medicines	44.08 Bn	44.08 Bn	-	-3.06
6	BeOne Medicines	39.95 Bn	34.85 Bn	1.53 Bn	2.12
7	Alnylam Pharmaceuticals	35.14 Bn	31.84 Bn	992.69 Mn	1.23
8	Royalty Pharma	28.44 Bn	27.60 Bn	-	0.18
9	Insmed	27.32 Bn	26.16 Bn	358.27 Mn	-0.06
10	Biohaven	2.35 Bn	2.08 Bn	-	-0.91

Historic Data

Download Data